Live Patient Cases to be Supported by BioSig’s PURE EP System During EPLive 2020

BioSig Technologies (NASDAQ: BSGM) is a medical technology company which designs and commercializes an innovative signal processing platform. Bio Sig’s signal processing platform is aimed to uncover the full range of ECG and intra-cardiac signals and to improve signal fidelity.

BioSig Technologies has recently announced that during EPLive 2020, the fifth international symposium on complex arrhythmias, its first product, the PURE EP system, would be featured in several live cases broadcast.

BioSig Resumes Clinical Activities with PURE EP System

Ken Londoner, Chairman and CEO of BioSig Technologies, has recently announced company’s plans to resume its clinical activities with patient cases at Texas Cardiac Arrhythmia Institute at St. David’s Medical Center in Austin, TX.

Ken Londoner has also shared that BioSig Technologies is actively negotiating with a number of other centers in order to continue its clinical activities and to initiate new installations of its PURE EP(tm) System.

Ken Londoner: BioSig is a tech platform company

Connecticut company BioSig Tech, began generating revenue from product sales, last November, after winning Food & Drug Administration approval in 2018 to sell its PURE EP system.

PURE EP™ Simulator Gets a U.S. Patent

On June 06, 2019, BioSig Technologies, Inc., a Westport, Conn.-based company that develops a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, announced that the U.S. Patent & Trademark Office allowed a U.S. patent application covering its electrophysiology simulator. The patent application number 15/103,278 entitled, "Systems and Methods For Evaluation of Electrophysiology Systems" was filed on June 9, 2016.